• Explore /
  • Poster
  • / A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER).

A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER).

Abstract Video & Slides Poster

Authors

null

Ignacio Melero

Universidad de Navarra, Center for Applied Medical Research (CIMA), Pamplona, Spain

Ignacio Melero , Emiliano Calvo , Reinhard Dummer , Elena Garralda , Martin H. Schuler , Maria-Elisabeth Goebeler , Ralf C. Bargou , Tanja Gromke , Josep Tabernero , Egle Ramelyte , Maria De Miguel , Miguel F. Sanmamed , Maria E. Rodriguez-Ruiz , Petra Fettes , Kathrin Klar , Manfred Ruediger , Christine Schuberth-Wagner , Markus Haake , Joerg Wischhusen , Eugen Leo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Clinical Trial Registration Number

NCT04725474

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2658)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2658

Abstract #

TPS2658

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Susanna Varkey Ulahannan

First Author: Soohyeon Lee

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

First Author: Jing Huang

First Author: Jin Li